Elena Shagisultanova
Title | Associate Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
|
|
|
Bibliographic
-
Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. Clin Cancer Res. 2023 12 15; 29(24):5021-5030. PMID: 37363965.
-
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20; 9(1):41. PMID: 37210417.
-
Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 06; 168:119-127. PMID: 35525161.
-
Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol. 2022 03; 6:e2100370. PMID: 35357905.
-
Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 01; 21(1):48-57. PMID: 34728571.
-
Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2021 Sep; 13(3):216-226. PMID: 34457184.
-
Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun; 187(3):883-891. PMID: 33625615.
-
West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618. PMID: 31407530.
-
Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res Treat. 2019 Sep; 177(2):369-382. PMID: 31254157.
-
Weiss J, Afghahi A, Shagisultanova E, Diamond JR. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer. Oncology (Williston Park). 2018 Oct 15; 32(10):513-5. PMID: 30334242.
-
Schedin TB, Borges VF, Shagisultanova E. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. Int J Breast Cancer. 2018; 2018:7835095. PMID: 30018827.
-
Shagisultanova E, Mayordomo J, Elias AD. Triple-negative breast cancer in the elderly. Breast J. 2017 11; 23(6):627-629. PMID: 29112794.
-
Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol Ther. 2017 Sep 02; 18(9):694-704. PMID: 28886275.
-
Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017 Jun 20; 8(25):39945-39962. PMID: 28591715.
-
Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503. PMID: 28404760.
-
Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70. PMID: 27987198.
-
Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther. 2016 10; 15(10):2486-2497. PMID: 27507850.
-
Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015 Aug 01; 567(1):1-11. PMID: 25967390.
-
Shagisultanova E, Dunbrack RL, Golemis EA. Issues in interpreting the in vivo activity of Aurora-A. Expert Opin Ther Targets. 2015 Feb; 19(2):187-200. PMID: 25384454.
-
Shagisultanova EI, Piao Z, Li HR, Malkhosyan SR. Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett. 2004 Dec 28; 216(2):221-6. PMID: 15533598.
-
Li HR, Shagisultanova EI, Yamashita K, Piao Z, Perucho M, Malkhosyan SR. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res. 2004 Jul 15; 64(14):4760-7. PMID: 15256444.
-
Shagisultanova EI, Novikova IA, Sidorenko YS, Marchenko GN, Strongin AY, Malkhosyan SR. The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res. 2004 Jan-Feb; 24(1):199-201. PMID: 15015597.
-
Mustafina OE, Shagisultanova EI, Tuktarova IA, Khusnutdinova EK. [Polymorphism of the apolipoprotein E gene and the risk of myocardial infarction]. Mol Biol (Mosk). 2002 Nov-Dec; 36(6):978-84. PMID: 12500534.
-
Mustafina OE, Shagisultanova EI, Tuktarova IA, Khusnutdinova EK. [Connection of HindIII-polymorphism of the lipoprotein lipase gene with risk of developing myocardial infarct]. Mol Biol (Mosk). 2001 May-Jun; 35(3):401-3. PMID: 11443920.
-
Mustafina OE, Shagisultanova EI, Nasibullin TR, Tuktarova IA, Bikmeeva AM, Poliudova ON, Khusnutdinova EK. [Endothelial nitric oxide synthase gene minisatellite polymorphism: study in populations of the Volga-Ural region and analysis of associations with myocardial infarct and essential hypertension]. Genetika. 2001 May; 37(5):668-74. PMID: 11436560.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2001 | 2 | 2002 | 1 | 2004 | 3 | 2014 | 1 | 2015 | 1 | 2016 | 2 | 2017 | 4 | 2018 | 2 | 2019 | 2 | 2021 | 3 | 2022 | 2 | 2023 | 2 |
To return to the timeline, click here.
|
Shagisultanova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|